Long-term use of XXXX reduces the risk of @entity303 : a nationwide population-based cohort study.

@entity1 @entity0 @entity440 @entity303 @entity5
BACKGROUND: To assess the possible association between @entity440 treatment and the subsequent risk of @entity303 in @entity1 with @entity0 , a population-based cohort study was conducted using the Taiwanese National Health Insurance Research Database. METHODS: The study cohort contained 24   197 @entity1 diagnosed with @entity0 between 1 January 2000 and 31 December 2004. Among them, 16   556 cases received @entity440 treatment and 7641 did not. Four @entity1 without @entity0 were frequency matched to each case by age and index-year as the @entity5 -free group. The outcome of the analysis of is @entity303 . Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariate Cox proportional hazards regression models. RESULTS: @entity1 with @entity0 exhibited a similar risk of developing @entity303 (adjusted HR   =   0.95, 95% CI   =   0.86-1.04) compared with the @entity5 -free group. In addition, among @entity1 diagnosed with @entity0 , @entity440 users exhibited a significant 17% lower risk of @entity303 compared with those not using @entity440 (adjusted HR   =   0.83, 95% CI   =   0.69-0.98), but the significant difference was limited to 5 years or more use (adjusted HR   =   0.47, 95% CI   =   0.32-0.69). Both @entity440 and aromatase inhibitor use had a joint effect, with a significantly lower risk of @entity303 among @entity1 . CONCLUSION: The results of this population-based cohort study suggest that long-term use of @entity440 in @entity1 with @entity0 is associated with a lower risk of @entity303 .
